Premium
Percutaneous Peptide Immunization via Corneum Barrier‐disrupted Murine Skin for Experimental Tumor Immunoprophylaxis
Author(s) -
TAKIGAWA MASAHIRO,
TOKURA YOSHIKI,
HASHIZUME HIDEO,
YAGI HIROAKI,
SEO NAOHIRO
Publication year - 2001
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2001.tb03717.x
Subject(s) - ctl* , stratum corneum , cytotoxic t cell , immunization , cancer research , peptide , immunotherapy , spleen , immunology , chemistry , antigen , medicine , pathology , immune system , cd8 , in vitro , biochemistry
A bstract : Percutaneous peptide immunization is a method in which tumor‐specific cytotoxic T lymphocytes (CTL) are primed in the lymph nodes and spleen following application of tumor peptides to corneum barrier‐disrupted murine skin. Immunized mice are protected against subsequent challenge with corresponding tumors and suppress the growth of established tumors. CTL expansion after peptide application seems to be mediated by epidermal Langerhans' cells. In the human, disruption of permeability barrier by tape stripping also induces activation of epidermal Langerhans' cells. Thus, percutaneous peptide immunization provides a simple and noninvasive means of inducing potent antitumor immunity that may be exploited for cancer immunotherapy in the human.